시장보고서

상품코드

2075472

트랜스티레틴 아밀로이드성 심근증(ATTR-CM) 치료제 시장 : 유형별, 약제 유형별, 유통 채널별, 지역별

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type, By Drug Type, By Distribution Channel, By Geography

발행일: 2026년 04월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,704,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,428,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,898,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

트랜스티레틴 아밀로이드성 심근증 치료제 시장은 2026년에 38억 2,000만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 257억 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 31.3%로 성장할 것으로 예측됩니다.

리포트 범위		리포트 상세
기준연도 :	2025년	2026년 시장 규모 :	38억 2,000만 달러
과거 데이터 기간 :	2020-2024년	예측 기간 :	2026-2033년
2026-2033년 예측 기간의 CAGR :	31.30%	2033년 시장 규모 예측 :	257억 달러

트랜스티레틴 아밀로이드성 심근증(ATTR-CM)은 아밀로이드증의 일반적인 유형 중 하나로, 심장에 영향을 미쳐 심근 경화를 유발하고, 결국 심부전으로 이어집니다. ATTR-CM은 피로, 호흡 곤란, 말초 부종 등의 심부전 증상이나 체내 아밀로이드 섬유 축적과 관련된 기타 증상을 유발하는 경우가 많습니다. 트랜스티레틴 아밀로이드성 심근증(ATTR-CM)에는 유전성 트랜스티레틴 아밀로이드증(hATTR)과 야생형 트랜스티레틴 아밀로이드증(wtATTR)의 두 가지 유형이 있습니다. 이 질환은 증상이 심각해진 후에야 비로소 진단되는 경우가 많습니다.

시장 역학

트랜스티레틴 아밀로이드성 심근증의 유병률 증가가 트랜스티레틴 아밀로이드성 심근증(ATTR-CM) 치료 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 미국 국립생물공학정보센터(NCBI)에 따르면 2019년 12월에 발표된 논문에 따르면 2010년 1월부터 2018년 9월까지의 병원 기반 데이터베이스인 ‘Japan Medical Data Vision(MDV)"을 활용한 연구 결과가 보고되어 있으며, 이를 바탕으로 현재 진단받은 ATTR-CM 환자 수를 추정하고 있습니다. 이 연구에서는 9년 이상에 걸친 조사 데이터가 보고되었으며, 3,255명(MDV 데이터베이스내 성인 환자 100만 명당 155.8명)에서 3,992명(동일 기준 191.1명)의 환자가 야생형 트랜스티레틴 아밀로이드증(wtATTR)으로 진단받은 것으로 나타났습니다.

그러나 트랜스티레틴 아밀로이드증성 심근병증(ATTR-CM)에 대한 인지도가 낮아 시장 성장을 저해할 것으로 예상됩니다. 예를 들어 2016년 아밀로이드증 재단이 발표한 기사에 따르면 일반인뿐만 아니라 의료 종사자들 사이에서도 트랜스티레틴 아밀로이드증성 심근병증(ATTR-CM)에 대한 인지도가 낮아, 이 질환은 간과되기 쉽습니다.

본 조사의 주요 특징 :

이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신약 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
이 조사에서는 다음의 매개변수를 바탕으로 전 세계 트랜스티레틴 아밀로이드성 심근증(ATTR-CM) 치료 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 시장내 입지, 유통 전략, 주요 발전 사항, 전략 및 향후 계획입니다.
이 보고서에서 도출된 인사이트는 기업의 마케팅 담당자 및 경영진이 향후 의약품 출시, 약물 분류의 업그레이드, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있도록 해줍니다.
이 '세계의 트랜스티레틴 아밀로이드성 심근증(ATTR-CM) 치료 시장' 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자 여러분은 전 세계 트랜스티레틴 아밀로이드성 심근증(ATTR-CM) 치료 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 3.82 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	31.30%	2033 Value Projection:	USD 25.70 Bn

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common type of amyloidosis, which affects the heart, causing heart muscles to stiffen and eventually lead to heart failure. ATTR-CM often causes symptoms of heart failure, such as fatigue, shortness of breath and peripheral edema, and other symptoms related to buildup of amyloid fibrils in the body. There are two forms of transthyretin amyloid cardiomyopathy (ATTR-CM); hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wtATTR). This disease is often diagnosed only after symptoms have become severe.

Market Dynamics

Rising incidence of transthyretin amyloid cardiomyopathy is expected to drive the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in December 2019, reports the study of the Japan Medical Data Vision (MDV), which was a hospital based database from January 2010 to September 2018 to estimate the number of currently diagnosed ATTR-CM patients. This study reports data of over 9 years of study which included 3255 patients (155.8 per million adult patients in the MDV database) to 3992 patients (191.1 per million) diagnoses of wild type transthyretin amyloidosis (wtATTR).

However, lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by Amyloidosis. Amyloidosis Foundation in 2016, awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) is low among the general public as well as healthcare professionals and therefore, this condition often is unnoticed.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., Corino Therapeutics, Inc. among others
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Detailed Segmentation:

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type (Revenue, USD Bn, 2021 - 2033)
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
Transthyretin Stabilizers
Nonsteroidal anti-inflammatory drugs (NSAID)
RNAi therapy
Others
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Type:
  - Hereditary Transthyretin Amyloidosis (hATTR)
  - Wild Type Transthyretin Amyloidosis (wtATTR)
- By Drug Type:
  - Transthyretin Stabilizers
  - Nonsteroidal anti-inflammatory drugs (NSAID)
  - RNAi therapy
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - U.S.
  - Canada
Latin America
- By Type:
  - Hereditary Transthyretin Amyloidosis (hATTR)
  - Wild Type Transthyretin Amyloidosis (wtATTR)
- By Drug Type:
  - Transthyretin Stabilizers
  - Nonsteroidal anti-inflammatory drugs (NSAID)
  - RNAi therapy
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Type:
  - Hereditary Transthyretin Amyloidosis (hATTR)
  - Wild Type Transthyretin Amyloidosis (wtATTR)
- By Drug Type:
  - Transthyretin Stabilizers
  - Nonsteroidal Anti-Inflammatory Drugs (NSAID)
  - RNAi therapy
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Type:
  - Hereditary Transthyretin Amyloidosis (hATTR)
  - Wild Type Transthyretin Amyloidosis (wtATTR)
- By Drug Type:
  - Transthyretin Stabilizers
  - Nonsteroidal Anti-Inflammatory Drugs (NSAID)
  - RNAi therapy
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Type:
  - Hereditary Transthyretin Amyloidosis (hATTR)
  - Wild Type Transthyretin Amyloidosis (wtATTR)
- By Drug Type:
  - Transthyretin Stabilizers
  - Nonsteroidal Anti-Inflammatory Drugs (NSAID)
  - RNAi therapy
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - Others
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Type:
  - Hereditary Transthyretin Amyloidosis (hATTR)
  - Wild Type Transthyretin Amyloidosis (wtATTR)
- By Drug Type:
  - Transthyretin Stabilizers
  - Nonsteroidal Anti-Inflammatory Drugs (NSAID)
  - RNAi therapy
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
GlaxoSmithKline Plc.
Eidos Therapeutics
Ionis Pharmaceuticals, Inc.
Alnylam Pharmaceuticals
Prothena Corporation plc
Intellia Therapeutics, Inc.
Corino Therapeutics, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Approvals/Launches
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Recent Trends
Pricing Analysis
Key Developments
PEST Analysis
Porter€(TM)s Analysis

4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

Economic Impact
Impact on Supply and Demand

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hereditary Transthyretin Amyloidosis (hATTR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Wild Type Transthyretin Amyloidosis (wtATTR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Transthyretin Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Nonsteroidal Anti-inflammatory Drugs (NSAID)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
RNAi Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

8. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GlaxoSmithKline Plc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eidos Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ionis Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Alnylam Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Prothena Corporation plc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Intellia Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Corino Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
Analysts€(TM) Views

10. Section

References
Research Methodology
About us and Sales Contact

트랜스티레틴 아밀로이드성 심근증(ATTR-CM) 치료제 시장 : 유형별, 약제 유형별, 유통 채널별, 지역별